Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=564 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
Metastatic Breast Cancer
Primary: Overall Survival (PP Population) — 30.2; 26.1 months — p=0.1983
Phase 2 N=237 A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Hormone Receptor Positive Breast Cancer · HER-2 Positive Breast Cancer
Primary: Progression Free Survival (PFS) — 8.3; 5.7; 5.7 Months — p=0.0506
Phase 2 N=58 Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 27 participants
Phase 2 N=151 Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
Breast Neoplasms · Breast Cancer · Estrogen-receptor Positive Breast Cancer
Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=29 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Breast Neoplasms
Primary: Objective Response (OR) — 80.0; 75.0; 36.4 Percentage of participants
Phase 2 N=43 BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
Breast Cancer
Primary: Phase I: Recommended Phase II Dose (RP2D) of BYL-719 (Alpelisib) + Nab-paclitaxel to be Used in Combination to Treat Advanced HER2-negative Breast Cancer — 350 mg
Phase 3 N=315 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
HER2-Positive Breast Carcinoma · Hormone Receptor-Positive Breast Carcinoma · Stage IB Breast Cancer AJCC v7
Primary: Percent of Patients With Pathological Complete Response (pCR) in the Breast and Post Therapy Lymph Nodes — 41.2; 45.8 percentage of participants
Phase 2 N=144 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast Neoplasms
Primary: Stage 1: Percentage of Participants With Objective Response — 10.0; 10.0; 26.9; 16.7 percentage of participants
Phase 2 N=124 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Phase 3 N=719 Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival (PFS) Per Investigators' Assessment Based on Local Radiology Review - Full Population — 14.95; 14.49 months — p=0.1166
Phase 3 N=569 Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
HER2/Neu Over-expressing Locally Advanced Breast Cancer · Metastatic Breast Cancer
Primary: Progressive-free Survival (PFS) Per Investigator Assessment — 7.00; 5.78 months — p=0.0067
Phase 3 N=601 Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 7.3; 9.4; 7.5; 10 month
Phase 2 N=141 Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response in Breast and Axillary Lymph Nodes. — 16; 14; 21; 5 Participants
Phase 2 N=40 DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
Advanced Breast Cancer · HER2-positive Breast Cancer · Brain Metastases
Primary: 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) — 1; 7 Participants
Phase 2 N=49 Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Malignant Neoplasm of Breast · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · Estrogen Receptor Positive Breast Cancer
Primary: Progression Free Survival (PFS) Per RECIST 1.1 — 9.13 Months
Phase 2 N=55 T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
HER2-positive Breast Cancer · Breast Cancer · Breast Cancer Stage
Primary: Estimate Progression-free Survival — 16.9; 8.3 Months
Phase 2 N=56 A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Locally Recurrent · Metastatic Breast Cancer ( HER2 Negative)
Primary: Objective Response Rate (ORR) — 28.6 Percentage of participants
Phase 3 N=991 A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC) — 53.5; 61.3 percentage of participants
Phase 2 N=8 A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
HER2+/HR+ Breast Cancer
Primary: Number of Participants With Dose-Limiting Toxicities — 1 Participants
Phase 3 N=652 Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010
Phase 2 N=42 Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
Breast Cancer
Primary: Phase Ib Primary Outcome: Proportion of Patients Who Experienced DLTs Attributable to Palbociclib, Tucatinib, or Both — 100; 65; 100 percentage of participants
Phase 3 N=502 Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
Advanced Metastatic Breast Cancer
Primary: Clinical Benefit Rate (CBR) in Women and Men With Hormone Receptor Positiv, HER-2 Negative Breast Cancer Treated With Ribocilib and Letrozole — 63.2; 57.7; 56.5; 60.8…
Phase 3 N=131 Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
Advanced Breast Cancer Female
Primary: Number of Participants With All-causality Treatment-emergent Adverse Events (TEAEs) — 0; 17; 82; 23 Participants
Phase 4 N=252 Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
Breast Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (All Causalities) — 92; 152; 244; 18 Participants
Phase 2 N=52 Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Breast Cancer
Primary: Objective Response Rate — 71.2 Percentage of participants
Phase 3 N=235 Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Post Menopausal Breast Cancer
Primary: Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades — 4; 0; 4; 195 Participants
Phase 3 N=330 A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer
Breast Cancer
Primary: Event-Free Survival (EFS) - Percentage of Participants With an Event — 40.0; 50.9; 42.4 percentage of participants
Phase 2 N=225 A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors…
Phase 4 N=70 A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane
HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Primary: Severity of Adverse Events — 53; 40; 18; 2 Participants